Astec Q1 FY27 Results: Revenue Down, Loss Narrows YoY
ASTEC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.7 pts more than Nifty Microcap 250 and 2.8 pts more than its Pesticides & Agrochemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Astec LifeSciences reported Q1 FY27 results for the quarter ended June 30, 2026. Consolidated revenue was Rs. 8,356 lakhs, down about 8 percent from Rs. 9,108 lakhs YoY. Net loss narrowed to Rs. 1,871 lakhs from Rs. 3,303 lakhs in Q1 FY26. EPS stood at Rs. (8.41). Auditor BSR and Co gave an unmodified limited review opinion. An exceptional item of Rs. 209 lakhs from Labour Codes impacted the FY26 full year results.
Loss narrows but revenue keeps declining; persistent agrochemical segment pressure may weigh on investor sentiment.